Diagnosis of central venous catheter-related thrombus by transesophageal echocardiography  by Gulbas, Z. et al.
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EFFICACY OF PEGFILGRASTIM (PF) FOR NEUTROPHIL RECOVERY AF-
TER AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
Frame, D.1, Drajer, D.1, Myint, H.2, Kang, E.1, Vujovic, M.1,
Fung, H.1 1. Rush University Medical Center, Chicago, IL; 2. Univer-
sity of Colorado Health Science Center, Aurora, CO.
Background: Daily ﬁlgrastim or sargramostim are commonly used
to decrease the time to neutrophil engraftment (NE) after ASCT.
Since a single 6 mg dose of PF has been shown to be as effective as
daily ﬁlgrastim (F) in decreasing the duration of neutropenia after
standard chemotherapy, this study explored the effectiveness of a
single dose of PF after high dose chemotherapy and ASCT in adults
withmultiple myeloma (MM) or lymphoma (L).Methods:Originally
5 patients (pts) were enrolled in a pilot study to determine the efﬁcacy,
safety, and kinetics of PF given on day 5 after stem cell infusion.
After efﬁcacy and safety was demonstrated in these patients the stan-
dard protocol was changed to use PF on day3 after ASCT. In total
16 pts have received PF after conditioning with melphalan (200
mg/m2) for MM (n 6) or Rituxan BEAM (n 6) or Rituxan-TBI-
Cyclophosphamide (n  4). A retrospective comparison was also
made to 60 pts who had received sargramostim(SM) for NE after
ASCT in the previous 12months.Results:All pts treated with PF had
engraftment of neutrophils and platelets. The median time to NE to
ANC 	 500 was 8.5 days (range 7–11) and to ANC 	 1000 was 9.3
days. Average CD34 cells infused were 4.9  106/kg. The median
time to platelet engraftment was 11.8 days (range 3–21). There were
no adverse events associated with PF. The retrospective analysis of 60
patients treated with SM resulted in median time to NE of 11 days
(range 9–14) with a median of 8 days of SM administration (range
6–11). Conclusions: A single dose of 6 mg PF administered SQ on
days 3 to 5 after ASCT is safe and results in rapid neutrophil
engraftment that appears to be at least comparable to daily SM. All
patients preferred the single injection. The platelet engraftment time
also appeared to be rapid. PF is a reasonable option in pts receiving
ASCT.
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DESCRIPTIVE ANALYSIS ON THE ROLE AND OUTCOMES OF PSYCHO-
LOGICAL EVALUATION AND INTERVENTION IN PATIENTS UNDERGO-
ING STEM CELL TRANSPLANT
Hoerster, C.M.1, Bachier, C.1, LeMaistre, C.F.1, Shaughnessy, P.1 1Texas
Transplant Institute Methodist Healthcare System, San Antonio, TX.
Background: Mental health problems often go undiagnosed
and can complicate the management of patients (pts) after stem
cell transplantation (SCT). In 2004, we established a clinical
service with deﬁned providers who focused on the mental health
needs of the SCT patients. Prior to this time pts were referred
to available community providers as needs were identiﬁed. This
descriptive retrospective study evaluates the practical utilization
of psychological and psychiatric services in the ﬁrst year of this
program and the role of mental health providers in a large SCT
program. Results: 172 pts underwent SCT in the 1-year period
designated for data analysis. Of these pts, 55 (32%) were re-
ferred for psychological services that included evaluation and
therapeutic intervention by a clinic psychologist. Of the pts
referred for psychological services, the average age was 47 years,
with 26 males and 28 females. Twenty-four were Caucasian, 15
were Hispanic, and 1 was African American. Pts were referred
for evaluation by SCT physicians, primarily for mood symp-
toms. These symptoms indicated depression, anxiety, or poor
general coping. Other reasons for referral included smoking
cessation, prior history of psychiatric illness, family issues, ste-
roid-related mania, cognitive changes, panic disorder, “denial”
of illness, and family dysfunction. DSM-IVR diagnoses included
major depressive disorder (14), mood disorder related to diag-
nosis and treatment (13), dual diagnosis, either with nicotine
dependence, drug or alcohol dependence with concurrent mood
disorder (12), and bipolar type disorder unrelated to medica-
tions (7). Diagnosis was deferred for 6 patients. Three patients
received adjustment related diagnoses. Twenty-four (40%) pts
evaluated by the psychologist were referred for further evalua-
tion for psychiatric medications by a psychiatrist or psychiatric
clinical nurse specialist. Thirty-one pts were placed on medica-
tions. Pts were followed throughout their pre- and post-trans-
plant course for an average of 6.4 sessions. Referrals for services
increased throughout the ﬁrst year of the program. Conclu-
sions: Results of this retrospective study reﬂect the utilization
of psychological services provided in the ﬁrst year of services.
The number of moderate to severe psychiatric diagnoses de-
notes the importance of the availability of psychological ser-
vices. The study establishes a need for continued prospective
research in this population with a focus on detection and devel-
opment of useful interventions.
409
BACTERIAL CONTAMINATION OF PLATELET CONCENTRATES: INACTI-
VATE OR SCREEN?
Grabmer, C.1, Lass-Floerl, C.2, Allersdorfer, D.1, Rheinschmidt, M.3,
Lin, L.3, Schoenitzer, D.1, Nussbaumer, W.1 1. Department of Trans-
fusion Medicine, University Hospital Innsbruck, Innsbruck, Austria; 2.
Institute for Hygiene and Social Medicine, University of Innsbruck,
Innsbruck, Austria; 3. Cerus Corporation, Concord, CA.
Background: Platelets (PLTs) are stored under conditions
that favor bacterial growth and therefore bacterial contamina-
tion is considered a serious problem in transfusion. Most fre-
quent indications for repeated PLT transfusions are neutro-
penic patients during ablative chemotherapy and the incidence
of non-fatal transfusion transmitted sepsis in these patients may
be under diagnosed. This study compares efﬁcacy of bacterial
screening (BacT/Alert) versus pathogen inactivation (INTER-
CEPT) of PLT concentrates before transfusion. Material and
Methods: 7 species of bacteria (Staphylococcus aureus, Staphylo-
coccus epidermidis, Streptococcus agalactiae, Klebsiella pneumoniae,
Escherichia coli, Propionibacterium acnes, and Clostridium perfrin-
gens) were inoculated at three different concentration levels
(1–10, 10–100, 100–1000 CFU/PLT unit) into double-dose
PLTs. After inoculation the units were divided and one of the
paired units was treated with INTERCEPT. Samples were
taken from both units on day 1, 2, and 5 of storage and inocu-
lated into culture bottles (BacT/Alert) to detect bacteria. PLTs
were considered negative if no bacterial growth was detected
after 120 hours of culture. Results: For untreated PLTs seeded
with 100–1000 CFU/unit of bacteria cultures were positive in
86% of units before day 5. Inoculation with 1–10 CFU/unit or
10–100 CFU/unit resulted in negative cultures in 71% and 43%
of units by day 5, respectively. All PLTs contaminated with
bacteria and treated with INTERCEPT remained negative
through day 5 regardless of species, level of contamination, and
sampling time. Conclusions: Bacterial detection using cultures
may fail to detect low levels of bacteria typically associated with
platelet contamination at time of collection and processing.
Failure to detect bacteria will result in the release of contami-
nated platelet products with “test negative-to-date” status. In
contrast, inactivation of bacteria is capable of preventing release
of contaminated platelet components.
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DIAGNOSIS OF CENTRAL VENOUS CATHETER-RELATED THROMBUS BY
TRANSESOPHAGEAL ECHOCARDIOGRAPHY
Gulbas, Z.1, Gunduz, E.1, Akay, M.1 1Eskisehir Osmangazi University,
Eskisehir, Turkey.
Thrombus at the tip of central venous catheters is a problem
frequently seen in patients receiveing intensive chemotherapy.
Because many catheter-related thrombi are asymptomatic, the
true incidence of this complication is difﬁcult to assess and is
likely underestimated. The major complication of the thrombus
is pulmonary embolism. The thrombus incidence observed by
TEE in asymptomatic patients is reported 12.5%. Our aim was
to assess the frequency of central venous catheter-related
thrombus before catheter removal in patients with hematolog-
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ical diseases by using TEE and to assess if the D-dimer test can
predict the presence of a central venous catheter-related throm-
bus. We assessed 37 patients with various hematological diseases
(18 AML, 8 NHL, 6 ALL, 2 MM, 1 HL, 1 primary amiloidosis,
and 1 MDS). Mean age was 37 years. Mean time with catheter
was 2.66 months. Fourteen of thirty-seven patients were trans-
planted. Thrombus was found in 8 of 37 patients (21.6%).
Thrombus incidence in transplanted group was 28.57% (4/14).
Thirty-four of the patients (91.9) were asymptomatic. No rela-
tion was found between thrombus and D-dimer levels (P 
.071). The time with catheter was not related with the presence
of thrombus also (P  .328). Our ﬁndings showed that TEE is
a useful method in evaluating the presence of thrombus at the
tip of central venous catheters, so it can be useful for the
prediction of complications due to thrombus before catheter
removal. D-dimer shows tendency to be useful in predicting the
presence of a thrombus.
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ATYPICAL MYCOBACTERIUM INFECTIONS IN PEDIATRIC PATIENTS UN-
DERGOING RELATED DONOR HEMATOPOIETIC STEM CELL TRANS-
PLANTATION (HSCT)
Dalal, J.D.1, Jackson, M.A.1, Gilman, A.2, Swanson, D.1,
Gonzalez, C.1, Jones, R.1, Shenoy, S.3, Woolfrey, A.4, Gamis, A.S.1,
Peters, C.1 1. Children’s Mercy Hospital, Kansas City, MO; 2. 2UNC
School of Medicine, Chapel Hill, NC; 3. Washington University Medical
Center, St. Louis, MO; 4. Fred Hutchinson Cancer Research Center,
Seattle, WA.
Atypical mycobacterium infections are uncommon in children
undergoing HSCT compared to solid organ transplant recipi-
ents or HIV patients, though more prevalent than in the general
population. Improvements in laboratory diagnostic methods
have led to more accurate and timely identiﬁcation of mycobac-
terium isolates. Diagnosis of non-tuberculus mycobacterium
(NTM) infection in immunocompromised children is difﬁcult
due to non-speciﬁc, diverse clinical manifestations. We report 3
pediatric patients who underwent related donor HSCT from
2002 to 2005 and developed deﬁnite NTM infections in the
setting of fever of unknown origin. Patient 3 was transplanted at
Fred Hutchinson Cancer Research Center, received donor lym-
phocyte infusion at CMH and was re-grafted at Washington
University Medical Center. CD4 counts were 	200/l at the
time of diagnosis. Of note, the CD4 count had just recovered in
patient 2 as has been reported in patients with AIDS developing
atypical mycobacterium osteomyelitis. All patients were immu-
nosuppressed at the time of NTM diagnosis. Aggresive local
treatment such as debridement followed by bone grafting and
insertion of appropriately coated antibiotic beads was essential
for treatment of NTM osteomyelitis. Patient 3 underwent a
second transplant and an alemtuzumab-based reduced intensity
conditioning regimen without NTM prophylaxis and did not
reactivate infection. Outcomes of NTM disease were all favor-
able after appropriate antimicrobial therapy. Susceptibility test-
ing of isolates with MIC was very helpful in choosing appropri-
ate outpatient treatment. The combination of newer macrolides,
ethambutol, rifabutin, and ﬂuoroquinolones appears to have
greater in vivo activity and to provide improved eradication of
bacteria compared to single agents. Concomitant surgical de-
bridement and removal of the central venous catheter when
indicated was essential. We conclude: (1) NTM infection can
cause fever of unknown origin in HSCT patients. (2) NTM
infection can be successfully treated in the outpatient clinic with
antimicrobials chosen according to susceptibility testing of pa-
tient isolates. (3) Local treatment such as catheter removal,
excisional biopsy, and surgical debridement are critical and can
be performed without delayed wound healing or the necessity of
skin grafting in the setting of active skin GVHD. (4) Subsequent
second HSCT can be performed without prophylaxis provided
that the prior NTM infection has been adequately treated (Ta-
ble 1).
Table 1. Patient Characteristics and Outcomes
Category Pt. 1 Pt. 2 Pt. 3
Diagnosis SCID AML IPEX
Age at HSCT 6 months 16 years 2 years
Stem Cells and
Match
maternal PBSC, 3
of 6
maternal PBSC, 3
of 6
BM, 6 of 6 sister
Preparation Flu/ATG Flu/TBI/Melphalan/
ATG
1: Flu/TBI; 2:
Campath/Flu/
Melphalan
GVHD prophylaxis/
treatment
TCD TCD 1: Tacrolimus,
MMF; 2:
Tacrolimus,
steroid
Vital Status alive alive alive
Engraftment full donor
chimerism
full donor
chimerism
1: mixed
chimerism; 2:
mixed chimerism
GVHD grade II acute grade II acute none
A. Mycobacterium
site
central line, lung tibia subcutaneous
Species M. chelonae/
abscessus
M. avium complex M.
chelonae/abscessus
Evaluation blood culture, CT
scan, lung biopsy
CT scan, MRI, bone
aspiration
CT scan, MRI,
excisional biopsy
Onset 6 months 39 days 22 months
Treatment &
Outcome
catheter removal,
ciprofloxacin,
azithromycin,
linezolid  6 wks;
resolved
azithromycin,
ethambutol,
linezolid  8
months,
debridement,
bone graft with
antibiotic beads
surgical excision;
cefoxitin,
azithromycin,
linezolid  8
months
Abbreviations: SCID, common gamma chain X-linked severe
combined immunodeﬁciency; AML, acute myelogenous leuke-
mia; IPEX, immune dysregulation, polyendocrinopathy, enter-
opathy, X-linked; PBSC, peripheral blood stem cells; BM, bone
marrow; Flu, ﬂudarabine; ATG, anti-thymocyte globulin; TBI,
total body irradiation; TCD, T-cell depletion; MMF, mycophe-
nolate mofetil
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A PHASE I SAFETY, TOLERABILITY, PHARMACOKINETIC, AND PHAR-
MACODYNAMIC ASSESSMENT OF VELAFERMIN IN PATIENTS WITH
ACTIVE ORAL MUCOSITIS
Mehta, J.1, Schuster, M.W.2, Harpel, J.2, Skikne, B.3, Shore, T.2,
Duffey, S.1, Greenberg, J.2, Divine, C.3, Halvorsen, Y.4, Cosentino, C.4,
Hahne, W.4 1. Northwestern U., Chicago, IL; 2. Cornell Med. Center,
New York, NY; 3. U. of Kansas Med. Ctr, Kansas City, KS; 4. CuraGen
Corp., Branford, CT.
Velafermin (CG53135-05) or recombinant human ﬁbroblast
growth factor-20 (rhFGF-20) protein is under investigation for the
treatment of active oral mucositis (OM). OM is a commonly
occurring side effect of high-dose chemotherapy (HDCT) in pa-
tients (pts) undergoing autologous hematopoietic stem cell trans-
plant (AHSCT) and in leukemia pts receiving CT. Pharmacology
studies demonstrated that treatment of velafermin to animals with
active OM for 2, 3, or 4 consecutive days resulted in a signiﬁcant
reduction in duration of clinically relevant OM compared with
animals in the vehicle treated control group. Previous clinical
studies showed that velafermin was generally well tolerated as a
single dose regimen up to 0.2 mg/kg dose level. The objectives of
this Phase I trial are to evaluate the safety, tolerability and phar-
macokinetics (PK) of velafermin when administered as three daily
doses via intravenous (IV) infusion to pts who develop oral mu-
cositis after receiving HDCT. OM and diarrhea status are evalu-
ated using the World Health Organization (WHO) grading sys-
tem. Approximately 9–12 pts receiving AHSCT following myelo-
ablative CT or leukemia pts receiving CT, age 18 years and older,
are to be enrolled when Grades 1 or 2 OM is observed. Velafermin
treatment is initiated within 24 hours after OM is observed. Three
pts will be treated at each dose level based on tolerability and
recruitment parameters. Pts will receive velafermin at 0.03, 0.1, or
0.2 mg/kg/day for 3 consecutive days. Pt follow-up will be contin-
ued for approximately 60 days following infusion of velafermin.
The 3 pts in the ﬁrst cohort receiving 0.03 mg/kg tolerated mul-
tiple doses of velafermin well with no complaints or adverse events
(AE) during or immediately after infusion. Dose escalation deci-
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